TSX · CURA.TO
Curaleaf Holdings, Inc.
CA$12.13+CA$0.22 (+1.85%)
Curaleaf Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.07% below the high.
Loading market information…
OTC · CRLBF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 07:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cresco Labs Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cresco Labs Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cresco Labs Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 30, 2025 | -$0.04-33.33% vs estimate | $165.76M+0.64% vs estimate |
|---|
| Q4 2024 | Mar 12, 2025 | -$0.010.0% vs estimate | $176.00M+1.5% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -$0.02-100.0% vs estimate | $179.78M-3.31% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$12.13+CA$0.22 (+1.85%)
Curaleaf Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.07% below the high.
$7.81+$0.12 (+1.56%)
Vireo Growth Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.09% below the high.
CA$5.74+CA$0.03 (+0.53%)
Aurora Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.4% below the high.
$2.29+$0.04 (+1.78%)
Glass House Brands Inc’s quoted price sits in the lower half of its reported 52-week range, 82.64% below the high.
CA$0.25+CA$0.02 (+6.52%)
Vext Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.75% below the high.
CA$0.12CA$0.00 (0.0%)
Planet 13 Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.09% below the high.
CA$0.01CA$0.00 (0.0%)
iAnthus Capital Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.05$0.00 (0.0%)
MariMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.88% below the high.
